anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
While a finger prick test accurately measures the blood glucose level, it does not provide continuous measurements and hence it is unreliable as a hypoglycaemia notification. Recent studies have indicated that the use of continuous glucose monitoring (CGM) reduces the risk of severe hypoglycaemia. However, some find these devices troublesome to use and are annoyed by the inaccuracy of the measurements and even after short-term use the coverage in subgroups of patients is as low as 50% of the time. Thus, there is a medical need for a reliable hypoglycaemia notification which is easy and convenient to use and with high sensitivity and high rate of positive prediction.

This clinical investigation is designed to evaluate the sensitivity and the positive predictive value of the Hyposafe H02 in subjects with type 1 diabetes during everyday activities and during insulin-induced hypoglycaemia. In addition, the investigation provides information regarding safety and usability of the device. This to verify that the Hyposafe H02 works as intended in subjects with type 1 diabetes before proceeding with a larger study in subjects with type 1 diabetes.
FIELD: medicine, pharmacology. SUBSTANCE: invention proposes a new cosmetic or pharmaceutic composition for local using for treatment of patients with itching (prurigo), ocular or palpebral pains and ocular or palpebral dysesthesia. Antagonist of substance P, preferably sendid or spantid-II in the amount 0.000001-5 wt.-% is used as an active component. Cosmetic composition can be used for making up or making up removal for sensitive eyes. EFFECT: broadened pattern of indicated agents. 13 cl, 4 ex
Salt-sensitive hypertension (SS-HT) is characterized by blood pressure elevation in response to high dietary salt intake and is considered to increase the risk of cardiovascular and renal morbidity. Although the mechanisms responsible for SS-HT are complex, the kidneys are known to play a central role in the development of SS-HT and the salt sensitivity of blood pressure (SSBP). Moreover, several factors influence renal function and SSBP, including the renin-angiotensin-aldosterone system, sympathetic nervous system, obesity, and aging. A phenotypic characteristic of SSBP is aberrant activation of the renin-angiotensin system and sympathetic nervous system in response to excessive salt intake. SSBP is also accompanied by a blunted increase in renal blood flow after salt loading, resulting in sodium retention and SS-HT. Obesity is associated with inappropriate activation of the aldosterone mineralocorticoid receptor pathway and renal sympathetic nervous system in response to excessive salt, and mineralocorticoid receptor antagonists and renal denervation attenuate sodium retention and inhibit salt-induced blood pressure elevation in obese dogs and humans. SSBP increases with age, which has been attributed to impaired renal sodium handling and a decline in renal function, even in the absence of kidney disease. Aging-associated changes in renal hemodynamics are accompanied by significant alterations in renal hormone levels and renal sodium handling, resulting in SS-HT. In this review, we focus mainly on the contribution of renal function to the development of SS-HT.
BIC is a substrate of CYP3A and UGT1A1. A drug that is a strong inducer of CYP3A and also an inducer of UGT1A1 can substantially decrease the plasma concentrations of BIC which may lead to loss of therapeutic effect of BIKTARVY and development of resistance [see Clinical Pharmacology (12.3)].

The use of BIKTARVY with a drug that is a strong inhibitor of CYP3A and also an inhibitor of UGT1A1 may significantly increase the plasma concentrations of BIC.

TAF is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Co-administration of drugs that inhibit P-gp and BCRP may increase the absorption and plasma concentrations of TAF [see Clinical Pharmacology (12.3)]. Co-administration of drugs that induce P-gp activity are expected to decrease the absorption of TAF, resulting in decreased plasma concentration of TAF, which may lead to loss of therapeutic effect of BIKTARVY and development of resistance (see Table 3).
<P>PROBLEM TO BE SOLVED: To provide a peptide effective for inducing cell death, in more detail, to provide a cell death-inducing agent to which a peptide having a cell death-inducing activity is applied, and to provide an anticancer agent.  <P>SOLUTION: This peptide having the amino acid sequence of SNLHL, and the peptide whose one or several amino acids are conservatively replaced. The cell death-inducing agent containing the peptide. The anti-cancer agent containing the peptide. And the medicine containing the peptide and used for treating cancer.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Participants who were previously enrolled, dosed, and completed approximately 43 days of TID EV administration. Participants are crossed over to receive BID administration of EV for approximately 43 additional days.
Cpds. of formula (I) and their pharmaceutically acceptable salts, and inters. of formula (II) are new: (where R1-4 are each H, halogen, alkyl or alkoxy; or any two of R1-4 together with the C atoms to which they are bonded may form an opt. substd. carbocycle; X is a direct bond or O). (I) are used for inhibiting the effects of certain antigen-antibody reactions, e.g., in the prophylaxis and treatment of asthma, hay-fever and in treatment of rhinitis. (I) may be administered orally, by injection or by inhalation, doses being 0.1-100 mg./kg./day.
Participants will receive no additional intervention. Participants will continue on their regular diet, which includes ≤1.5 dairy serving/day.
The present invention provides antagonists to cell adhesion useful in controlling the negative effects of inflammation, and the metastasis of cancer cells. These antagonists are ligands to E-selectin containing the sialyl Le x  structure, including sialyl Le x  glycoproteins, sialyl Le x  glycolipids, and sialyl Le x  oligsaccharides, and other related sialyl Le x -containing molecules capable of inhibiting E-selectin mediated cell adhesion to endothelial cells. The present invention also provides antibodies against sialyl Le x  determinants capable of interrupting E-selectin mediated cell adhesion, which are also considered antagonists according to the present invention. The present invention also provides methods of using the antagonists of the present invention to reduce inflammation, and methods to inhibit the process of metastasis by carcinogenic cells. The present invention-also provides nucleic acid molecules encoding the glycoprotein antagonists of the present invention, in particular soluble chimeric leukosialin, and vectors capable of expressing these nucleic acid molecules, as well as cells capable of producing sialyl Le x  positive recombinant glycoproteins. The present invention further provides a method of determining metastatic potential by comparing the efficiency of E-selectin-mediated adhesion of cell samples. In addition the present invention provides a method of producing a preferred antagonist of the present invention, sialyl Le x  positive glycoproteins, in particular, sialy Le x  positive chimeric leukosialin.
OBJECTIVES: Cancerous transformation in mature cystic ovarian teratoma is rare. Herein, we reported a case of squamous cell carcinoma transformation in mature cystic ovarian teratoma and performed an in-depth literature review to highlight the risk factors, prognosis, and suggested treatment for these patients.
CASE PRESENTATION: We report a 66-years old postmenopausal woman diagnosed with a 120×90 (mm) mass at the left adnexa compatible with mature cystic ovarian teratoma. Following resection, the histopathological investigations showed malignant transformation in her mature cystic ovarian teratoma, and the immunohistochemistry for cytokeratin (CK) 5/6 and tumor protein 63 (P63) indicated squamous cell carcinoma transformation. She has been observed for her stage IA tumor and has been cancer-free for 6 months.
CONCLUSIONS: Although malignant transformation in mature cystic ovarian teratoma is rare, it should be suspected if certain risk factors, e.g., elderly and high tumor size, exist. Stage IA patients' prognosis is favorable, and chemotherapy is not recommended.
<P>PROBLEM TO BE SOLVED: To provide a knockout animal in which EphB6 receptor genes are destroyed and to provide a method for utilizing the same.  <P>SOLUTION: An EphB6 knockout mouse is obtained by modifying all or a part of DNA sequences of the EphB6 receptor genes in the genome and is a mouse in which both the EphB6 receptor genes on the homologous chromosome are destroyed. The EphB6 knockout mouse can be prepared by using, e.g. a genetic targeting method for replacing a region containing at least an initiation codon of the EphB6 receptor genes in the genome with another base sequence by homologous recombination. Furthermore, the knockout mouse can be utilized for functional analyses of the EphB6 genes and has various utilities.  <P>COPYRIGHT: (C)2004,JPO
In a recent study, we have shown that the systematic use of oral nutritional supplements (ONS) in combination with counseling further favours the maintenance of nutrition status, the recovery of quality of life and, more importantly, improves the practicability of CT-RT. This effect would be substantially attributable to the increase in protein-energy intake associated with ONS use, but also to the possible "nutraceutical" action of omega-3 fatty acids. Therefore, modulation of the inflammatory response could play a role during cancer treatments. In this context, there is an already-known high-calorie-high-protein nutritional blend, enriched in immunonutrients (arginine, nucleotides and omega-3 fatty acids), which could also have an application in this type of patients. This mixture has proven effective in reducing the risk of post-operative complications (e.g. infections, fistulas, etc.) and the length of stay of patients undergoing major cancer surgery (abdominal and head and neck regions). Nevertheless, in oncology, there is a growing therapeutic interest in the modulation of inflammation and immunosuppression at the tumour microenvironment level.
PURPOSE:To improve the operator's operability by securing such a system where the diagnosis frequency is automatically calculated and displayed with input of the area data showing the diagnosed areas and a key code showing the diagnosis contents. CONSTITUTION:For the window jobs, a patient code and a date are first inputted through a keyboard 1 and a tooth formula key is pushed to display a reticle on the screen of a CRT display 2 together with input of a tooth number. Thus a tooth formula showing the diagnosed areas is supplied and then a key code showing the diagnosis contents is supplied. Then the input tooth formula is stored in a fixed buffer 8 and at the same time plural diagnosis item data included in the input key code are read out to a processing subject buffer 7 from a diagnosis code part 12 of a diagnosis code file 5. Then the area unit identification data contained in the read-out diagnosis item data is discriminated and an arithmetic processing part 9 carries out the corresponding arithmetic processing in response to the contents of the area unit identification data. Thus the countable maximum frequency is calculated for each diagnosis item.
Metastasis has been one of the primary reasons for the high mortality rates associated with tumours in recent years, rendering the treatment of current malignancies challenging and representing a significant cause of recurrence in patients who have undergone surgical tumour resection. Halting tumour metastasis has become an essential goal for achieving favourable prognoses following cancer treatment. In recent years, increasing clarity in understanding the mechanisms underlying metastasis has been achieved. The concept of premetastatic niches has gained widespread acceptance, which posits that tumour cells establish a unique microenvironment at distant sites prior to their migration, facilitating their settlement and growth at those locations. Neutrophils serve as crucial constituents of the premetastatic niche, actively shaping its microenvironmental characteristics, which include immunosuppression, inflammation, angiogenesis and extracellular matrix remodelling. These characteristics are intimately associated with the successful engraftment and subsequent progression of tumour cells. As our understanding of the role and significance of neutrophils in the premetastatic niche deepens, leveraging the presence of neutrophils within the premetastatic niche has gradually attracted the interest of researchers as a potential therapeutic target. The focal point of this review revolves around elucidating the involvement of neutrophils in the formation and shaping of the premetastatic niche (PMN), alongside the introduction of emerging therapeutic approaches aimed at impeding cancer metastasis.
The field of pulmonology saw significant advances in 2023. The publications highlighted in this article address advances and changes in practice related to asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pleural disorders, and sleep-disordered breathing. One article reviews data examining the efficacy of vaccination against respiratory syncytial virus, a respiratory viral illness that has had devastating effects globally. Four studies evaluate the role of various therapies in COPD, including dupilumab, ensifentrine, pulmonary rehabilitation programs, and lung volume reduction versus endobronchial valves. Another study explores the effect on vascular events of positive-pressure ventilation in patients with sleep-disordered breathing and recent stroke. The use of combination therapy with rituximab and mycophenolate mofetil on progression-free survival in patients with nonspecific interstitial pneumonia is the topic of another study. We also highlight an update of clinical recommendations for the evaluation of patients with pleural disorders and a systematic review analyzing the effectiveness of inhaled corticosteroids as a supplement to dual therapy for COPD.
Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
PURPOSE:To provide the subject ointment containing oleanolic acid as the active component, useful for remedy of skin diseases, e.g. decubitus, burn ulcer, skin ulcer developing on the skin of a rheumatic, frostbite and pruritus and low in toxicity. CONSTITUTION:Oleanolic acid is used in an amount of 0.01-1wt.% as the active component and an oily material, an emulsifier, a dispersant, a wetting agent, a stabilizer, etc., respectively used conventionally are suitably blended therewith. The resultant mixture is prepared using the conventional method to obtain the objective drug. As the dosage form, ointment, lotion liniment, aerosol, etc., are possible. Oleanolic acid is obtained by extracting leaves of a Japanese privet, a Japanese angelica and olive, concentrating the extract, hydrolyzing the resultant concentrated extract and treating the hydrolyzed extract using the column chromatography method or recrystallizing the hydrolyzed extract.
The invention discloses a novel hopane type triterpene compound which is rare in natural products at present has fracture at 2 and 3 positions and has the molecule formula of C30H48O3. The compound can be obtained from a plant of which the Latin name is Megacodonstylophorus (C.B.Clarke) H.Smith. Comprehensive analysis of two-dimension nuclear magnetic resonance spectrum and X-ray diffraction confirms the chemical structure and the spatial configuration of the compound. The invention further discloses a preparation method of the compound. In addition, the in-vitro anti-tumor experiment shows that the compound has a remarkable inhibition function on dozens of tumor cell stains. The compound provides a novel lead compound for researching novel anti-tumor medicines, and is significant for Tibetan medicine resource development and utilization.
Arformoterol, the (R,R)-enantiomer of formoterol, is a selective long-acting beta2-adrenergic receptor agonist (beta2-agonist) that has two-fold greater potency than racemic formoterol (which contains both the (S,S) and (R,R)-enantiomers). The (S,S)-enantiomer is about 1,000-fold less potent as a beta2-agonist than the (R,R)-enantiomer. While it is recognized that beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, data indicate that there are also beta2-receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects.  
  


The pharmacologic effects of beta2-adrenoceptor agonist drugs, including arformoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased intracellular cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.  
  


In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Arformoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness. The relevance of these in vitro and animal findings to humans is unknown.
Methylprednisolone sodium succinate is contraindicated: 

  * in systemic fungal infections and patients with known hypersensitivity to the product and its constituents. The methylprednisolone sodium succinate, 40 mg presentation includes lactose monohydrate produced from cow’s milk. This presentation is therefore contraindicated in patients with a known or suspected hypersensitivity to cow’s milk or its components or other dairy products because it may contain trace amounts of milk ingredients. 
  * for intrathecal administration. Reports of severe medical events have been associated with this route of administration. 



Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. 

After mixing as directed, methylprednisolone contains benzyl alcohol. The use of methylprednisolone, reconstituted with benzyl alcohol, is contraindicated for use in premature infants (see WARNINGS and PRECAUTIONS, Pediatric Use).
These patients will be submitted to 2 daily sessions of cerebral stimulation, starting from the first day after the surgery, for 4 consecutive days, with each session having 20 minutes, and a minimum break of 8 hours between them. Will be applied a direct current stimulus of 2 milliampere (mA) in the right anode and in the left cathode on the prefrontal right region.
The invention relates to immunoconjugates made of egg-yolk antibodies (IgY), the production and use thereof in diagnoses and therapy. The aim of the invention is to provide alternative products to traditional immunoconjugates for use in diagnoses and therapy. The inventive immunoconjugates are superior to monoclonal antibodies and immune serums from mammals in addition to IgY preparations from conventional hens in terms of purity and antigen targeting. The invention seeks to avoid the formation of human anti-IgY antibodies as far as possible, and to produce immunoconjugates in large quantities at a low price in a manner which is compatible with animal welfare. This is achieved by polyclonal IgY conjugates from intact egg-yolk antibodies (IgY), IgY fragments, Fab constructions or humanized egg-yolk antibodies form SPF hens, preferably from transgenic SPF hens. The antibodies or antibody fragments are conjugated as immunologically effective components with at least one other component such as a signaling substance, an active substance or an amplifier module.
Standard of care for the follow-up, no use of remote monitoring or digital therapeutics for the first 12 weeks. After 12 weeks, option is given to the patient to use the full Continuum solution for another period of 12 weeks.
Our everyday perceptual experiences are grounded in the integration of information within and across our senses. Due to this direct behavioural relevance, cross-modal integration retains a certain degree of contextual flexibility, even to social relevance. However, how social relevance modulates cross-modal integration remains unclear. To investigate possible mechanisms, Experiment 1 tested the principles of audio-visual integration for numerosity estimation by deriving a Bayesian optimal observer model with perceptual prior from empirical data to explain perceptual biases. Such perceptual priors may shift towards locations of high salience in the stimulus space. Our results showed that the tendency to over- or underestimate numerosity, expressed in the frequency and strength of fission and fusion illusions, depended on the actual event numerosity. Experiment 2 replicated the effects of social relevance on multisensory integration from Scheller & Sui, 2022 JEP:HPP, using a lower number of events, thereby favouring the opposite illusion through enhanced influences of the prior. In line with the idea that the self acts like a prior, the more frequently observed illusion (more malleable to prior influences) was modulated by self-relevance. Our findings suggest that the self can influence perception by acting like a prior in cue integration, biasing perceptual estimates towards areas of high self-relevance.
Vadadustat was not carcinogenic when administered orally at doses of 2, 7, and 20 mg/kg/day in a 6-month study in transgenic mice and at doses of 5, 15, and 50 mg/kg/day in a 2-year study in rats. The highest exposure to vadadustat in rats corresponds to 0.2 times the MRHD based on AUC.

Vadadustat was negative for mutagenicity in the in vitro bacterial reverse mutation assay. Vadadustat exhibited clastogenic activity in vitro but was negative in the in vivo chromosomal aberration assay in peripheral blood lymphocytes and comet assay in rats. Based on the weight of evidence, vadadustat is not considered genotoxic.

Fertility and early embryonic development toxicity studies were conducted in rats at dose levels of 40 to 120 mg/kg/day. Vadadustat did not impact fertility or reproduction in rats up to 80 mg/kg/day (1.5 times the MRHD based on AUC).